Etubics Platform Generates Solid Immune Response in Colorectal Cancer Patients

Published: May 06, 2013

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

SEATTLE--(BUSINESS WIRE)--Etubics Corporation, a clinical stage bio-pharmaceutical company with a proprietary vaccine platform that results in a long lasting "active" immune response, announced today results from a first-in-man, Phase I/II clinical trial for its immunotherapy product candidate targeting carcinoembryonic antigen (CEA)-expressing cancers, such as colorectal cancer. The immunotherapy drug, called ETBX-011, induced an immune response in advanced colorectal cancer patients and gave encouraging overall survival results.

Help employers find you! Check out all the jobs and post your resume.

Back to news